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Abstract Constipation is a common and often debilitating
condition in the elderly, which may be caused by under-
lying disease conditions, structural abnormalities in the
bowel, and a variety of medications such as anticholiner-
gics, antidepressants, and opiates. In this review, we focus
on opioid-induced constipation (OIC), which is often
underrecognized and undertreated in the elderly. When
opioid therapy is initiated, healthcare providers are
encouraged to evaluate risk factors for the development of
constipation as part of a thorough patient history. To this
end, the patient assessment should include the use of val-
idated instruments, such as the Bristol Stool Scale and
Bowel Function Index, to confirm the diagnosis and pro-
vide a basis for evaluating treatment outcomes. Healthcare
providers should use a stepwise approach to the treatment
of OIC in the elderly. Conventional laxatives are a first-line
option and considered well tolerated with short-term use as
needed; however, evidence is lacking to support their
effectiveness in OIC. Moreover, because of the risk of
adverse events and other considerations, such as chewing
difficulties and swallowing disorders, conventional oral
laxatives may be inappropriate for the treatment of OIC in
the elderly. Thus, the availability of new pharmacologic
agents such as the peripherally acting l-opioid receptor
antagonists methylnaltrexone and naloxegol, which target
the underlying causes of OIC, and the secretagogue
lubiprostone may provide more effective treatment options
for elderly patients with OIC.
Key Points
Constipation is a prevalent and often debilitating
condition in the elderly, which may be caused by
underlying disease conditions, structural
abnormalities in the bowel, and a variety of
medications that are commonly used in this age
group.
Opioid-induced constipation (OIC), a debilitating
adverse event resulting from the agonist actions of
opioid medications at l-opioid receptors, which are
abundant throughout the gastrointestinal tract, is
often underrecognized and undertreated in the
elderly.
Healthcare providers should perform a thorough
patient assessment to evaluate risk factors for the
development of constipation in elderly patients,
recognizing the potential impact of different care
settings, underlying comorbidities (and medications
for their treatment), and the differentiation of OIC
from functional constipation as crucial aspects in
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1 Introduction
Constipation is a common and uncomfortable condition,
affecting an estimated 2–27 % of the general population in
the USA [1]. However, the incidence is much higher in the
elderly and ranges from 20 to 74 % of patients, depending
on the care setting [2–4], and negatively impacts quality of
life [5, 6]. The etiology of constipation in the elderly is
often multifactorial and may be associated with the pres-
ence of comorbidities [7, 8], the use of medications (e.g.,
anticholinergics and antidepressants) [9, 10], and sedentary
lifestyles [7].
The use of opioid analgesics is often associated with
the onset of opioid-induced bowel dysfunction (OBD),
which comprises a constellation of gastrointestinal (GI)
symptoms including abdominal bloating, gastrointestinal
reflux, abdominal cramps, and constipation [11, 12]. The
constipation resulting from opioid pain management
alone can be debilitating and is estimated to affect
40–86 % of patients being treated for noncancer pain
and cancer-related pain [12–18]. Although constipation
in general is a well-recognized condition in adult
patients, including the elderly [19], studies suggest that
OIC in the elderly is often underrecognized and under-
treated [20–23].
For these reasons, the present review aims to help
healthcare providers to better understand the risk factors
for constipation in elderly patients in the context of dif-
ferent care settings and underlying comorbidities for
effective management of this condition, with particular
focus on OIC.
2 Prevalence of Constipation and Pain
in the Elderly
Constipation is generally considered a condition in which
bowel movements (BMs) occur less often than usual and/or
consist of hard, lumpy stools that are difficult or painful to
pass [24]. Although it is difficult to define what represents
‘‘normal’’ bowel function across individuals [16], it is
typical to consider an adult who has not had a BM in
3 days as constipated [25]. Consequently, the prevalence of
constipation varies and has been estimated to range from
approximately 2 to 27 % across studies in the general
population of North America [1]. The prevalence of self-
reported constipation also increases with age and differs by
sex. Thus, the frequency of constipation tends to be greater
in patients at least 80 years of age compared with younger
individuals (66 vs 57 % of those aged \70 years) and is
more common in women compared with men (63 vs
54 %); women at least 60 years of age are twice as likely
as men to report being ‘‘always’’ or ‘‘mostly’’ constipated
[26]. Moreover, the frequency of emergency department
visits for constipation rose by approximately 13 % from
2006 to 2011 in patients C65 years of age [27], further
underscoring the burden of illness and the importance of
recognition and effective management of constipation in
the elderly.
Different care settings impact the prevalence rates for
constipation in older patients. For example, a lower
prevalence of constipation has been reported among inde-
pendent community-dwelling individuals (14–25 %)
[2, 28, 29] than among patients in the hospitalized acute
care (42–83 %) [30–32], hospice (45–70 %) [33–35], and
long-term care settings (47–55 %) [36, 37]. In addition, a
longitudinal survey conducted in the community setting
revealed that[60 % of those who reported constipation at
baseline continued to suffer from the condition at follow-
up 10 years later [28].
The prevalence of chronic pain in the elderly ranges
from 24 to 62 % in the community setting [38–41] and
from 64 to 83 % in the long-term care setting [42, 43].
Chronic pain often persists for longer durations in the
elderly compared with younger age groups [44, 45] and is
associated with a more sedentary lifestyle [46, 47]. In
addition to lower levels of physical activity, chronic pain in
the elderly confers an additional disease burden, most
commonly presenting as cardiac disorders (54 %), GI dis-
orders (36 %), psychiatric disorders (33 %), and obesity
(i.e., body mass index C30; 26 %) [41, 48]. Elderly women
are twice as likely as men to experience chronic pain
[41, 49, 50].
Opioid analgesics are recommended for the treatment
of chronic pain in the elderly [51] and are prescribed to
36–90 % of adult patients for the treatment of chronic
pain [52–54]. Although opioids provide effective pain
management, 25–86 % of elderly patients taking these
analgesics may have symptoms of OIC, and such patients
frequently report additional GI symptoms (e.g., loss of
appetite, gastroesophageal reflux) of OBD (Fig. 1)
[14, 21].
3 Pathophysiology
Constipation can present as normal or slow colon transit
constipation, either alone or in combination with defeca-
tory disorders [55]. Constipation can also occur secondary
to extrinsic factors, such as lack of dietary fiber or physical
inactivity, and can be caused by systemic diseases, medi-
cations, or structural abnormalities in the bowel (Table 1)
[56–59].
By definition, functional constipation has no specifically
identifiable underlying pathophysiologic mechanism. OIC,
on the other hand, is caused by opioid medications via
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direct agonism of l-opioid receptors, which are abundant
throughout the GI tract [60–62], the direct effect of which
results in delayed GI transit, decreased secretion of elec-
trolytes resulting in increased fluid absorption, and increased
sphincter tone with impaired reflex relaxation following
rectal distension [11, 12, 62]. Additionally, l-opioid recep-
tors are widely distributed throughout the central and
peripheral nervous systems [63, 64]; therefore, it is impor-
tant to strike a balance between the pain-relieving effects of
opioid analgesics, which are primarily mediated by agonism
at central l-opioid receptors, and the risk of GI effects of
opioids such as OIC, which can compromise the potential
clinical benefits of opioid analgesics by patients choosing to
decrease or stop the use of opioid medications to self-
manage their OIC and facilitate a BM [13].
4 Clinical Evaluation of Constipation
Optimal patient management depends on differentiating
functional constipation and secondary constipation caused
by neurologic disorders or medications other than opioids
(e.g., calcium channel antagonists, antidepressants) from
other causes such as OIC, which may occur in patients
receiving chronic opioid pharmacotherapy for noncancer
pain and cancer-related pain [65]. According to the Rome III
diagnostic criteria (Table 2), functional constipation is
characterized by infrequent, incomplete, and difficult BMs
without physiologic abnormalities that would explain the
condition. It is also characterized by the presence of at least
two of the following symptoms for at least 3 months:\3
BMs per week, stool hardness, straining, sensation of
GERD
Epigastric Discomfort
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Fig. 1 Prevalence of gastrointestinal symptoms in elderly patients
with opioid-induced constipation. GERD gastroesophageal reflux
disease. (Adapted from [14], reprinted by permission of Taylor &
Francis Ltd)
Table 1 Factors commonly associated with the onset of constipation in the elderly [57–59]
Medical conditionsa Medicationsa Structural abnormalitiesb
Electrolyte disturbances Analgesics (opioids, tramadol, NSAIDs) Carcinomas (colon, rectum, pancreas, stomach)
Hypercalcemia Antacids (calcium and aluminum) Colonic stricture (ischemic, inflammatory)
Hypokalemia Anticholinergics Radiation fibrosis
Hypermagnesemia Anticonvulsants Surgical complications (adhesions)
Endocrine and metabolic disorders Antihistamines
Diabetes mellitus Antiparkinsonian drugs (dopaminergic agents)
Hypothyroidism Antipsychotics (phenothiazine derivatives)
Hyperparathyroidism Bile acid binders
Chronic renal disease Calcium channel blockers
Myopathic disorders Calcium supplements
Amyloidosis Diuretics (furosemide, hydrochlorothiazide)
Scleroderma Iron supplements









NSAID nonsteroidal anti-inflammatory drug
a From [57], reprinted by permission of Dove Medical Press Ltd.
b Data from Hutchison [58] and Woolery et al. [59]
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incomplete evacuation or anorectal blockage, or the
requirement for manual maneuvers with at least 25 % of
BMs [11, 24]. Patients’ self-reporting of functional consti-
pation is frequently based on subjective impressions, such as
difficulty in having a BM, the presence of hard stools, and a
sensation of abdominal pain and bloating [26, 55].
To provide a standardized approach to the evaluation of
OIC, a multidisciplinary working group developed a con-
sensus definition of OIC as ‘‘a change when initiating
opioid therapy from baseline bowel habits that is charac-
terized by any of the following: reduced bowel movement
frequency, development or worsening of straining to pass
bowel movements, a sense of incomplete rectal evacuation,
or harder stool consistency’’ [66]. Symptoms commonly
reported by patients with OIC are similar to those reported
by patients with functional constipation [13, 66, 67].
In addition to presenting as a new condition secondary
to treatment with opioids, preexisting constipation can be
aggravated by opioids [68, 69], even in patients who have
received prophylactic treatment with osmotic or stimulant
laxatives [69, 70]. Despite the availability of a consensus
definition of OIC, the condition is often underrecognized
and undertreated [9, 20, 21]. As a result, many patients
with OIC continue to experience bothersome symptoms
and often decrease or stop their use of opioid medications
to reduce the symptoms of constipation, thereby compro-
mising pain management and quality of life (QOL)
[67, 71]. However, this is an unreliable approach to pain
management because the constipation-inducing dose of
opioid medication is typically 25 % of the dose that alle-
viates pain [72].
4.1 Opioid-Induced Constipation and Quality
of Life
Although OIC may result in changes in opioid dosing in
many patients, there is limited information on how this
condition impacts the quality of life (QOL) burden in
elderly patients with noncancer pain. In one study, patients
(mean age 50 years) with OIC reported significantly worse
scores on the both the mental (44.8 vs 41.6; P\ 0.05) and
physical components (34.9 vs 31.5; P\ 0.05) of the Short
Form-8 health-related QOL survey compared with patients
(mean age 52 years) without OIC [73]. In another study in
younger patients (mean age 53 years) with OIC and
chronic noncancer pain, the EuroQOL-5D (EQ-5D;
1 = full health, 0 = death) score reported at baseline
(mean ± SD 0.49 ± 0.29) was consistent with decreased
QOL [67]. In a study that evaluated QOL in patients using
opioids, patients with advanced illness and OIC (mean age
[64 years) reported significantly worse scores on the
Patient Assessment of Constipation-Quality of Life (PAC-
QOL) survey (Fig. 2a). Patients with non-advanced illness
and OIC (mean age 59 years) reported significantly worse
scores on both the PAC-QOL survey (Fig. 2a) and the EQ-
5D index (Fig. 2b) compared with patients (mean age
59 years) with non-advanced illness [74].
The impact of OIC over time on QOL in elderly patients
with noncancer pain has not been fully evaluated. In one
study, patients (mean age 61 years) with primarily non-
cancer pain and severe OIC reported a significantly worse
QOL score (0 = worst possible, 10 = best possible) over a
6-month period (constipation score 3.8; P\ 0.05) com-
pared with patients with no (4.9), mild (4.9), and moderate
(4.7) constipation [75]. In addition, when asked to rate their
satisfaction with their pain treatment on a 10-point scale
(0 = very dissatisfied, 10 = very satisfied) over a 6-month
period, patients with severe constipation reported signifi-
cantly less satisfaction with their pain treatment (mean
satisfaction score 5.2; P\ 0.05), compared with patients
with no (6.6), mild (6.6), and moderate (6.2) constipation
[75].
In another study, patients (mean age 54 years) with OIC
and chronic noncancer pain [predominantly back pain
Table 2 Rome III diagnostic
criteria for functional
constipation
Diagnostic criteria: specific symptomology
C2 of the following symptoms:
Straining during C25 % of BMs
Lumpy/hard stools in C25 % of BMs
Sensation of incomplete evacuation or anorectal obstruction/blockage in C25 % of BMs
Manual maneuvers to facilitate C25 % of defecationsa
\3 BMs/week
Loose stools rarely present without laxative use
Insufficient criteria for IBS
Adapted with permission from [24]
BM bowel movement, IBS irritable bowel syndrome
a Examples include digital evacuation and pelvic floor support
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(74.4 %) and joint pain (53.4 %)] reported a moderate
impact of OIC on quality of life, based on PAC-QOL
domain scores (range 0–4; higher scores indicate greater
impact) for physical discomfort (mean ± SD 2.0 ± 0.9),
psychological discomfort (1.3 ± 0.9), and worries and
concerns (1.8 ± 1.0) [76]. Moreover, PAC-QOL domain
scores remained relatively unchanged over a 24-week fol-
low-up period despite sufficient laxative use by[80 % of
patients in the 2 weeks before baseline and by[70 % of
patients throughout the 24-week follow-up period. Taken
together, these studies suggest that the burden of OIC on
quality of life may be affected by the patient’s health status
and persist over time despite sufficient laxative use.
4.2 Constipation in Different Care Settings
The risk of development or aggravation of constipation in
the elderly is contingent on a number of factors, which may
vary, depending on the care setting (Table 3). In the in-
dependent community setting, for example, significant risk
factors for constipation are abdominal pain [2], lower uri-
nary tract symptoms [77], body mass index C25 [77], use
of acetaminophen (C7 tablets/week) [78], use of opioid
analgesics [28], and any use of aspirin or nonsteroidal anti-
inflammatory drugs (NSAIDs) [78].
In the hospitalized acute care setting, the use of medi-
cations such as opioids, NSAIDs, diuretics, hypnotics,
muscle relaxants, statins, iron supplements, antimuscarinic
drugs, and drugs for Parkinson disease confer risk of
developing constipation (Table 1) [79–82]. Chewing diffi-
culty, a history of cerebrovascular events, acute exacerba-
tion of chronic obstructive pulmonary disease, or spinal
cord lesions can also independently aggravate constipation
[81, 83].
Elderly patients in the long-term care setting are at risk
of developing constipation from a variety of factors. These
include comorbidities such as Parkinson disease, pneumo-
nia, the presence of allergies, and cognitive impairment
[84, 85]; a sedentary lifestyle [84, 85]; decreased fluid
intake (\5 glasses/day) [85], inadequate dietary fiber, and
chewing problems [85]; poor nutritional assessment (i.e.,
Mini Nutritional Assessment score \17) [85]; polyphar-
macy ([5-7 drugs) [84, 85]; lack of privacy [86, 87]; and
dependence on caregivers [88].
In the setting of hospice care, the majority of patients
(54 %) with moderate to severe constipation at first
assessment had a primary diagnosis of cancer (trachea,
bronchus, and lung: 17 %; digestive organs and peri-
toneum: 14 %) or a nonmalignant medical condition
(46 %) such as a circulatory (15 %), cardiac (11 %), or
respiratory system disorder (7 %) [89]. In these patients,
the most significant risk factors for development of con-
stipation were insufficient food and fluid intake, a lack of
privacy, dependence on caregivers, and poor performance
status [90].
It is evident, therefore, that it is important to consider
the patient’s care setting and the risk factors that could
further exacerbate constipation to minimize the incidence
of this disorder, especially in those receiving opioids.
4.3 Identification of Vulnerable Elderly Patients
Regardless of setting, there are common factors that
increase susceptibility to constipation in general and to
OIC. Compared with individuals\65 years of age, elderly
individuals with constipation often report more frequent
straining, hard stools, self-digitation, sensation of rectal
































































Fig. 2 Quality of life in opioid-treated patients classified as having
advanced illness (severe, non-curable disease and relatively short life-
expectancy) or non-advanced illness (disabling but not life-threaten-
ing chronic condition) based on a PAC-QOL sum scores (higher
scores indicate lower quality of life) and b the EQ-5D index (lower
scores indicate lower quality of life). EQ-5D EuroQOL-5 Dimen-
sions, PAC–QOL Patient Assessment of Constipation–Quality of Life.
(Adapted from [74], reprinted by permission of Informa Healthcare)
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have more comorbidities that must be carefully monitored
and considered when diagnosing and managing OIC. These
include endocrine and metabolic disorders, such as diabetes
mellitus and chronic renal disease, and neurologic disor-
ders, including cerebrovascular disease, Parkinson disease,
and spinal cord injury [57].
The patient’s functional status should also be taken into
account; many elderly patients have sedentary lifestyles
and cognitive impairments [57]. Specific medications
including analgesics, tricyclic antidepressants, and anti-
cholinergic agents (Tables 1, 3) can further exacerbate OIC
[7, 10, 57, 78]. Lastly, insufficient intake of dietary fiber
and fluids is a common problem in the elderly, awareness
of which needs to be promoted among patients when
commencing opioid therapy [7, 63, 90, 91].
4.4 Risk of Developing Complications
from Untreated Constipation
As previously mentioned, several comorbid conditions can
aggravate constipation in general, but studies further
suggest that elderly individuals with constipation may be at
increased risk of developing additional medical complica-
tions. For example, increased straining to have a BM has
been associated with the onset of cardiovascular events,
including congestive heart failure and myocardial infarc-
tion, and cerebrovascular events, including transient
ischemic attacks and syncopal episodes [7, 92].
Elderly patients with chronic constipation may also be at
risk of developing new GI comorbidities, including
megacolon, volvulus, and anal fissures; and other comor-
bidities such as depression and mood disorders, iron defi-
ciency anemia, and hypothyroidism [93]. In the nursing
home setting, chronic untreated constipation is a risk factor
for the development of fecal impaction, which can cause
stercoral ulceration, leading to bowel perforation [94].
Physicians have expressed concern that, if not treated,
OIC could have serious consequences in the elderly beyond
the additional GI symptoms associated with OBD, includ-
ing fecal impaction and bowel obstruction, which may
contribute to increased patient morbidity (e.g., abdominal
pain, nausea and vomiting) [13, 52, 95–98]. Thus, it is
Table 3 Risk factors for the development of constipation in the elderly in different care settings
Community dwelling
[2, 28, 77, 78]
Hospitalized acute care
[79–83]
Long-term care [84–88] Hospice care [89, 90]
Abdominal pain Comorbidities Chewing problems Cancer (e.g., trachea, bronchus, lung)
BMI C 25 Acute exacerbation of COPD Comorbidities Dependence on caregivers
Lower urinary tract symptoms Cerebrovascular events Arthritis Insufficient food and fluid intake
Medications Chewing difficulties Anorexia nervosa Nonmalignant comorbidities
Acetaminophen C7 tablets/week Spinal cord lesions CV disease Circulatory
Antiparkinsonian drugs Medications Cognitive impairment Cardiac
Aspirin or NSAIDs Antimuscarinic drugs Parkinson disease Last pain score C mild
Diuretics Antiparkinsonian drugs Pneumonia Respiratory
Opioid analgesics Diuretics Postoperative pain (immobility) Poor performance status
Tricyclic antidepressants Hypnotics Presence of allergies Toileting facilities (e.g., lack of privacy)
Muscle relaxants Decreased fluid intake (\5 glasses/day)
NSAIDs Dependence on caregivers














Toileting facilities (e.g., lack of privacy)
BMI body mass index, COPD chronic obstructive pulmonary disease, CV cardiovascular, NSAID nonsteroidal anti-inflammatory drug
a Other than verapamil and nifedipine
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important that healthcare providers be aware of possible
risk factors (e.g., anorexia, immobility, cognitive impair-
ment, colonic neuromuscular disorders, urinary frequency)
for fecal impaction and bowel obstruction, and monitor
elderly patients accordingly [7, 99]. Reports of stercoral
perforation of the bowel, a potentially fatal condition
caused by fecal impaction, are rare in patients with OIC
[100], and the risk of other medical complications, such as
those previously mentioned in elderly patients with chronic
constipation in general, has not been fully evaluated in
elderly patients with OIC [101].
5 Clinical Management of Opioid-Induced
Constipation
Although nonpharmacologic and pharmacologic agents are
available for the management of constipation, most studies
were not designed to address the issues associated with
constipation in the elderly, including OIC. Treatment
guidelines specifically for the management of elderly
patients with OIC are not available. However, a review of
the evidence in the literature for treatment of adult patients
with OIC and noncancer pain recommends nonpharmaco-
logic interventions (e.g., dietary measures, increased
physical activity, biofeedback training) and use of over-
the-counter laxatives followed by prescription opioid
receptor antagonists if these fail [8, 63, 102].
5.1 Dietary Measures
Consistent with the association between insufficient food
and fluid and increased risk of constipation in palliative care
patients [90], increased food and fluid intake by patients in
the community (N = 27; mean age 64 years) and nursing
home settings (N = 23;[ 60 years of age) was associated
with significant improvements in Patient Assessment of
Constipation–Symptoms total scores and abdominal, rectal,
and stool symptom subscale scores [103, 104]. In addition to
improving symptoms of constipation, dietary measures such
a high fiber diet and increased fluid intake have been shown
to increase stool weight and decrease colon transit time in
some patients with constipation. Even so, it is unclear whe-
ther the effectiveness of dietary measures observed in
patients with functional constipation can be extrapolated to
elderly patients with OIC (Table 4) [8, 10, 11].
5.2 Physical Activity
Consistent with the ability of physical activity to increase
colonic motility following exercise [105], a randomized
study conducted in outpatients (N = 43)[45 years of age
with chronic constipation demonstrated that a 12-week
program of regular daily physical exercise improved sev-
eral symptoms of constipation (e.g., incomplete BM,
straining, hard stools) [106]. However, elderly patients
(N = 224; mean age 81 years) with constipation in the
long-term care setting showed no improvement in the fre-
quency of BMs as a result of either resistance training or
physical activity performed twice weekly for 6 months
under the guidance of a trained physical therapist [107].
5.3 Biofeedback Therapy
Biofeedback therapy is a form of behavioral modification
in which patients are trained to relax muscles of the anus
and pelvic floor and use their abdominal muscles to create a
pushing force that results in a BM [108]. Biofeedback
therapy may be used in the elderly; one study showed long-
term improvement in symptoms of chronic constipation in
patients (some of whom were elderly) followed for up to
nearly 4 years [10]. However, it is important to note that
biofeedback therapy and physical activity as interventions
for constipation in the elderly may not be useful in patients
with diminished cognitive function and other comorbidi-
ties, including chronic pain [4, 10, 63, 109].
5.4 Laxatives
Laxatives commonly used for treatment of constipation
include agents that inhibit fluid reabsorption, increase the
fluid content in the bowel on the basis of hydrophilic and
osmotic properties, or normalize contraction of the bowel
(Table 4) [12, 66]. Laxatives recommended as first-line
therapy in patients with OIC include stimulant laxatives
and stool softeners [63, 66]. However, there is insufficient
evidence from randomized clinical trials to determine
whether individual laxatives are better than others for the
management of constipation in the elderly [110], including
those with OIC [66].
It is worth noting that proactive, prophylactic treatment
of OIC is not routinely practiced in elderly patients. A
survey in elderly patients in the ambulatory care setting
revealed that only 1 % of patients received prescriptions
for laxatives when initiating opioid therapy for chronic
pain [111]. Moreover, a study in patients (mean age
53 years) with OIC and noncancer pain revealed an inad-
equate response to laxatives (e.g., osmotic laxatives, lac-
tulose, lubiprostone, and methylnaltrexone) in 94 % of
patients within the previous 2 weeks [67], indicating that
such patients are undertreated by commonly used laxatives.
Importantly, healthcare providers should be cognizant of
the fact that lifestyle interventions and laxative therapies
that have been used successfully for the treatment of con-
stipation in younger patients may be unsuccessful or
unrealistic in an elderly population (Table 4).
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Table 4 Interventions for the treatment of opioid-induced constipation and potential limitations for their use in elderly patients





Increases stool weight/hydration and
decreases colonic transit time
Effectiveness of increased dietary fiber in OIC
not established
Poor response to dietary fiber C30 g/day in
patients with slow-transit constipation and
dyssynergic defecation
Reluctance to increase fluid intake due to
perceived risk of becoming incontinent
May be ineffective in patients with chewing/
swallowing disorders
Failed to reduce laxative use or improve
symptoms of constipation in acute care
setting
[4, 87, 142, 143]
Physical activity Stimulates colonic activity after exercise Chronic pain may limit patient’s ability to






Increases stool bulk, distends colon,
stimulates peristalsis
Risk of AEs: gas, bloating, and rectal bleeding
May be unsuitable for treatment of OIC owing
to prevention of peristalsis by opioids, which
may result in exacerbation of abdominal pain
The need to drink sufficient fluids to avoid
mechanical obstruction may limit utility in
frail, immobile patients
Not recommended for relief of severe
constipation in palliative care settings




Increases fluid content of bowel lumen to
hydrate and soften stool, leading to
improved propulsion
Risk of AEs
PEG 3350: rectal bleeding, diarrhea, nausea,
vomiting, abdominal pain, bloating
Lactulose: gaseous distention, belching,
flatulence, borborygmi, abdominal
discomfort
Increased risk of aspiration of PEG-balanced
electrolyte solution in elderly with
supranuclear palsy or Parkinson disease
PEG may increase risk of folate deficiency in
frail elderly patients
Sweet taste of lactulose disagreeable to some
patients




Increases muscle contractions via enteric
reflex
Risk of AEs
Senna: diarrhea, abdominal pain, abdominal
cramps
Bisacodyl: stomach discomfort, faintness,
cramps, rectal burning
Slower onset of response (i.e.,[8-12 h) in
frail elderly
Risk of electrolyte disturbances (e.g.,





Emulsifier facilitates admixture of fat and
water in feces to soften the stool
Risk of rectal bleeding [10, 63, 147]
Secretagogue
[lubiprostone]
Chloride channel activator bypasses
antisecretory effects of opiates to increase
intestinal fluid secretion motility, facilitating
passage of stool
Risk of nausea, diarrhea [126]
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5.5 Opioid-Induced Constipation–Targeted
Pharmacotherapy
In elderly patients with OIC and chronic pain who do not
respond to lifestyle interventions or laxatives, relief from
symptoms of OIC may be achieved using agents that target
the underlying causes of constipation, such as methylnal-
trexone and naloxegol, and are indicated for the treatment
of OIC [112–115].
Peripherally acting l-opioid receptor antagonists
(PAMORAs), such as methylnaltrexone and naloxegol,
have a limited ability to penetrate the blood–brain barrier
and selectively antagonize peripheral l-opioid receptors in
the GI tract, thereby decreasing the constipating effects of
opioids while preserving centrally mediated opioid anal-
gesia [112, 114, 115].
5.5.1 Methylnaltrexone
Methylnaltrexone is approved for use in adult patients with
OIC and advanced disease when laxative response is
insufficient in the palliative care setting, as well as for use
in adult patients with chronic noncancer pain and OIC
[115]. In one clinical trial, patients (median age 72 years)
with OIC and advanced disease who received subcutaneous
methylnaltrexone (0.15 mg/kg body weight) every other
day (QOD) for 2 weeks reported a significantly higher rate
of laxation within 4 h of the first dose (48 vs 15 %,
P\ 0.001) and within 4 h after two or more of the first
four doses (52 vs 8 %, P\ 0.001) compared with placebo,
and there were no changes in pain scores, consistent with a
peripheral mechanism of action [116].
A 2-week study showed that patients (mean age 66 years)
with OIC, advanced disease (cancer in 66 %), and pain
(median daily morphine equivalent dose 177 mg/day) who
were randomized to receive fixed-dose subcutaneous
methylnaltrexone (8 or 12 mg QOD based on body weight)
reported a higher rate of rescue-free BMs (RFBMs) within
4 h after two or more of the first four doses (i.e., during the
first week; 62.9 vs 9.6 %, P\ 0.0001), an increased number
of BMs within 24 h after dosing (week 1, 4.9 vs 3.0,
P\ 0.0001; week 2, 3.2 vs 2.2, P = 0.0083), a greater
number of RFBMs within 24 h after dosing (week 1, 4.9 vs
2.7, P\ 0.0001; week 2, 3.2 vs 2.0, P = 0.0024), and
decreased use of rescue laxatives (27.2 vs 39.6 %,
P = 0.002) compared with placebo [117]. The effectiveness
observed during the 2-week period was maintained in a
10-week open-label extension (OLE) study [117]. In the
aforementioned studies, analgesia was maintained, mean
daily opioid doses remained stable, and fixed-dose subcu-
taneous methylnaltrexone was generally safe and well tol-
erated in patients with OIC and advanced disease [117].
Adult patients with OIC and chronic noncancer pain
(primarily back pain) who received methylnaltrexone
12 mg once daily (QD) or QOD reported an improvement
in rescue-free laxation (34.2 vs 9.9 %, P\ 0.001). There
was also an improvement in the number of injections
resulting in rescue-free laxation (QD dosing, 28.9 vs 9.4 %,
P\ 0.001; QOD dosing, 30.2 vs 9.3 %, P\ 0.001) within
4 h of the first dose of study medication. In addition,
treatment with methylnaltrexone resulted in significant
improvement in straining, completeness of evacuation, and
Bristol Stool Form Scale scores compared with placebo,
while maintaining opioid analgesia during the course of
treatment [118].
In patients (median age 72 years) with noncancer pain,
OIC and advanced disease who received subcutaneous
methylnaltrexone (0.15 mg/kg body weight) QOD for
2 weeks, the incidence of overall adverse events (AEs) was
similar in patients who received methylnaltrexone (81 %
Table 4 continued
Intervention Mechanism of action Potential limitations in elderly patients References
PAMORAs
Methylnaltrexone Functions as l-opioid receptor antagonist in GI
tract with limited ability to cross BBB;
decreases constipating effects of opioids
without compromising centrally mediated
opioid analgesia
Risk of abdominal pain, nausea, diarrhea,
hyperhidrosis, hot flush, tremor, chills
[115]
Naloxegol Functions as l-opioid receptor antagonist in GI
tract; reduced permeability and increased
efflux of naloxegol across BBB limits
potential for interference with centrally
mediated opioid analgesia
Risk of abdominal pain, diarrhea, nausea,
flatulence, vomiting, headache, hyperhidrosis
Contraindicated in patients with
known/suspected GI obstruction or at
increased risk of recurrent obstruction
[114]
Biofeedback Patients trained to relax pelvic floor muscles
during straining to have BMs
Usefulness compromised in patients with
cognitive impairment
[4, 10]
AE adverse event, BBB blood–brain barrier, BM bowel movement, GI gastrointestinal, OIC opioid-induced constipation, PAMORA peripherally
acting l-opioid receptor antagonist, PEG polyethylene glycol
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vs 80 %) compared with placebo [116]. However, AEs that
occurred more frequently with methylnaltrexone compared
with placebo included abdominal pain (17 vs 13 %), flat-
ulence (13 vs 7 %), nausea (11 vs 7 %), increase in body
temperature (8 vs 3 %), dizziness (8 vs 3 %), and diarrhea
(6 vs 4 %) [116].
In patients (mean age 66 years) with OIC and advanced
disease (cancer in 66 %) and pain who received fixed-dose
subcutaneous methylnaltrexone (8 or 12 mg QOD) for
2 weeks, the overall incidence of AEs was greater with
methylnaltrexone (randomized placebo-controlled trial
[RCT], 81.9 %; OLE phase, 90.6 %) compared with pla-
cebo (73.7 %, RCT) [117]. The most common AEs that
occurred more frequently with methylnaltrexone compared
with placebo were abdominal pain (33.6 vs 16.7 %), back
pain (7.8 vs 2.6 %), falling (7.8 vs 3.5 %), and flatulence
(6.9 vs 4.4 %) in the 2-week RCT phase; abdominal pain
(26.8 %), peripheral edema (17.4 %), diarrhea (16.1 %),
confusional state (15.4 %), nausea (14.1 %), and falling
(14.1 %) were reported by [10 % of patients in the
10-week OLE phase [117].
In adult patients with OIC and chronic noncancer pain
who received methylnaltrexone 12 mg QD or QOD, the
overall incidence of treatment-emergent adverse events
(TEAEs) was greater in patients who received methylnal-
trexone QD (49.3 %) or QOD (45.3 %) compared with
placebo (38.3 %) [118]. GI AEs that were more frequent in
the methylnaltrexone QD or QOD group compared with
placebo included abdominal pain (methylnaltrexone QD
and QOD, 19.3 and 15.5 %; placebo, 3.7 %), diarrhea (6.0
and 11.5 vs 3.7 %), and nausea (8.7 and 11.5 vs 6.2 %); the
incidence of hyperhidrosis was also greater in patients
receiving methylnaltrexone compared with placebo (6.0
and 6.1 vs 1.2 %) [118].
Maintenance of analgesia was observed, and subcuta-
neous methylnaltrexone was generally well tolerated in
patients with chronic pain [118], including those with
advanced illness [116, 117]. An oral formulation of
methylnaltrexone is in development [119] and, if approved
for use, may provide an alternative route of administration
with potential clinical value for patients and healthcare
providers.
5.5.2 Naloxegol
Naloxegol is a PEGylated derivative of the l-opioid
receptor antagonist naloxone for targeted oral treatment of
OIC in adults [114, 120]. In two phase 3, double-blind
studies of adults (11 % aged C65 and 2 % C75 years) with
noncancer pain, patients treated with naloxegol 25 mg
reported significantly higher 12-week response rates [C3
spontaneous BMs (SBMs) per week and an increase from
baseline of C1 SBM for C9 of 12 weeks and for C3 of the
final 4 weeks] compared with placebo (study 1, 44.4 vs
29.4 %, P = 0.001; study 2, 39.7 vs 29.3 %, P = 0.02);
response rates for the 12.5 mg dose versus placebo were
significantly higher in study 1 (40.8 vs 29.4 %, P = 0.02)
[114, 121]. Similar findings for response rates in patients
with an inadequate response to laxatives were reported for
naloxegol 25 mg versus placebo (study 1, 48.7 vs 28.8 %,
P = 0.002; study 2, 46.8 vs 31.4 %, P = 0.01) and for
naloxegol 12.5 mg versus placebo in study 1 (42.6 vs
28.8 %, P = 0.03) [121, 122]. In these studies, there were
no differences in effectiveness between elderly patients
C65 years of age and younger patients [114].
There was a reduction in rescue medication use for
naloxegol 25 mg (study 1, 54.7 %; study 2, 57.3 %) and
naloxegol 12.5 mg (study 1, 63.4 %; study 2, 57.3 %)
compared with placebo (study 1, 72.0 %; study 2, 70.7 %)
[121]. Patients also reported greater improvements in
straining, stool consistency (Bristol Stool Scale scores),
and percentage of days per week with a complete SBM for
naloxegol 25 mg compared with placebo in both studies
and for naloxegol 12.5 mg compared with placebo in study
2 (P\ 0.05) [121].
Naloxegol has generally been well tolerated in clinical
trials to date. A greater incidence of overall AEs was
reported in the naloxegol 25 mg group (study 1, 61.2 %;
study 2, 69.0 %) compared with the naloxegol 12.5 mg
(study 1, 49.3 %; study 2, 59.6 %) and placebo (study 1,
46.9 %; study 2, 58.9 %) groups [121]. AEs that occurred
more frequently in the naloxegol 25 mg group were pri-
marily GI in nature, including abdominal pain (study 1,
12.6 %; study 2, 19.0 %), diarrhea (study 1, 9.3 %; study
2, 9.1 %), nausea (study 1, 7.5 %; study 2, 8.6 %), and
flatulence (study 1, 5.6 %; study 2, 6.0 %) [121].
Elderly patients C65 years of age with noncancer pain
and OIC were also evaluated in a pooled analysis of these
two phase 3, double-blind, 12-week studies. The incidence
of overall AEs reported in the naloxegol 25 mg group
(56.6 %) was similar to that in the naloxegol 12.5 mg
group (50.0 %) and the placebo group (62.0 %) [123]. AEs
that occurred more frequently in the naloxegol 25 mg
group were primarily GI and included diarrhea (11.3 %),
nausea (11.3 %), abdominal pain (9.4 %), and vomiting
(7.5 %) [123].
Patients with noncancer pain and OIC were also evalu-
ated in a 52-week, open-label, randomized study of
naloxegol 25 mg compared with usual care treatment, in
which naloxegol was generally well tolerated [124]. The
incidence of overall AEs was 81.8 % with naloxegol and
72.2 % with usual care [124]. TEAEs that occurred more
frequently with naloxegol compared with usual care
included abdominal pain (17.8 vs 3.3 %), diarrhea (12.9 vs
5.9 %), nausea (9.4 vs 4.1 %), headache (9.0 vs 4.8 %),
flatulence (6.9 vs 1.1 %), and upper abdominal pain (5.1 vs
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1.1 %) [124]. Among elderly patients C65 years of age in
this 52-week study, the overall incidence of AEs was
86.7 % for naloxegol and 83.9 % for usual care [123].
TEAEs that occurred more frequently with naloxegol
compared with usual care in elderly patients included
diarrhea (13.3 vs 9.7 %), back pain (11.1 vs 6.5 %),
headache (8.9 vs 0 %), nausea (6.7 vs 0 %), abdominal
discomfort (6.7 vs 3.2 %), and sinusitis (6.7 vs 3.2 %)
[123].
In both the 12-week and 52-week studies of naloxegol,
analgesia was maintained, mean daily opioid doses
remained stable, and signs of opioid withdrawal were
infrequent [121, 124], consistent with the mechanism of
action of naloxegol in antagonizing peripheral l-opioid
receptors located in the GI tract.
5.6 Lubiprostone
Lubiprostone is a chloride channel activator, which
increases fluid secretion within the bowel lumen, thereby
softening stools and promoting BMs [125]. It was approved
in 2006 for the treatment of chronic idiopathic constipation
in adults and in 2013 for the treatment of OIC in adult
patients with chronic noncancer pain [126]. Patients with
noncancer pain and OIC who were administered oral
lubiprostone (24 lg twice daily [BID]) reported significant
improvement from baseline in the frequency of SBMs after
8 weeks compared with placebo (3.3 vs 2.4 SBMs/week,
P = 0.005) and in the overall change from baseline (2.2 vs
1.6 SBMs/week, P = 0.005) [127]. The number of patients
reporting a first SBM within 24 h (P = 0.018) and 48 h
(P = 0.05) was also greater for lubiprostone compared
with placebo, and improvements in other constipation-re-
lated symptoms (e.g., stool consistency, constipation
severity, straining) were observed [127].
In a multinational, phase 3 study in adult patients with
OIC and noncancer pain, a significantly greater percentage
of patients administered lubiprostone (24 lg BID) were
overall responders [reporting at least a moderate response
(C1 SBM improvement over baseline for all treatment
weeks for which observed data were available) as well as a
full response (C3 additional SBMs per week for at least 9
of the 12 treatment weeks after 12 weeks; 27.1 vs 18.9 %,
P = 0.03)] compared with placebo. Significant improve-
ments in straining, stool consistency, and constipation
severity were also observed [128].
In an OLE of these two 12-week studies, treatment
with lubiprostone (24 lg BID) maintained the improve-
ment in mean SBM frequency (range 4.9–5.3/week vs
1.4/week at baseline) over the 9-month treatment period;
significant improvements from baseline for SBM and
BM frequency were reported at each month (P\ 0.001,
all months). Significant improvements in symptoms
associated with constipation (straining, abdominal bloat-
ing, abdominal discomfort, constipation severity, stool
consistency, bowel habit regularity) were observed at
monthly intervals (months 1–9, P\ 0.001, all months)
[129].
In patients with OIC and noncancer pain who were
administered oral lubiprostone (24 lg BID), the overall
incidence of AEs was greater in patients who received
lubiprostone (63.5 vs 54.4 %) compared with placebo
[127]. AEs that occurred more frequently in the
lubiprostone group compared with placebo were GI in
nature and included nausea (16.8 vs 5.8 %), diarrhea
(9.6 % vs 2.9 %), and abdominal distention (8.2 % vs
2.4 %) [127].
In a multinational phase 3 study in adult patients with
OIC and noncancer pain who received oral lubiprostone
(24 lg BID), the overall incidence of TEAEs was similar
in patients who received lubiprostone (55.2 vs 49.5 %)
compared with placebo [128]. TEAEs reported more
commonly in the lubiprostone group compared with pla-
cebo included diarrhea (11.3 vs 3.8 %), nausea (9.9 vs
4.7 %), and abdominal pain (7.1 vs 0 %) [128].
In an OLE of two 12-week studies in adult patients with
OIC who were administered lubiprostone (24 lg BID), the
most common TEAEs during the 9-month treatment period
were nausea (5.0 %), diarrhea (4.6 %), headache (1.6 %),
and vomiting (1.4 %) [129].
Lubiprostone was generally well tolerated and did not
interfere with opioid-induced analgesia, which is reflected
in the stability of pain scores; however, in the 9-month
open-label study, the mean morphine equivalent daily dose
was not different at months 1–5 and month 9 (P C 0.09)
but was significantly increased at months 6–8 (P\ 0.04)
when compared with baseline [127–129].
5.7 Cost Effectiveness of Drugs for Treatment
of Opioid-Induced Constipation
Opioid-induced constipation (OIC) increases direct and
indirect healthcare costs, increases certain aspects of
healthcare utilization, and negatively impacts work pro-
ductivity [67, 73, 75, 130]. Moreover, healthcare costs are
reportedly higher for patients with severe OIC compared
with mild or moderate OIC [75]. Although effective
management of OIC has the potential for reducing
healthcare costs in elderly patients receiving opioids for
chronic pain [131], limited information is available on the
cost effectiveness of OIC treatments. Thus, longitudinal
data are needed to better understand the cost effectiveness
of drugs such as PAMORAs and lubiprostone in the
management of OIC in elderly patients.
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6 Clinical Guidance on Choice of Treatment
in Elderly Patients
6.1 Patient Medical History
According to American Gastroenterological Association
guidelines and recommendations by an American
Academy of Pain Medicine consensus panel, when a
healthcare provider suspects a defecatory disorder, patients
should be evaluated for a change in bowel habits, specific
symptoms of constipation, and the use of medications for
the treatment of constipation [25, 113, 132]. In addition to
the patient’s medical history (Fig. 3), one of the most
crucial factors on which to base clinical management
Yes
No
Elderly patient presents with constipation
History and physical examination to rule out red flagsaAre there red flags?
Non opioid?
Secondary to drugs/medications?
Patient clinically diagnosed with OIC 
What is the healthcare setting?










Has the aggressive laxative regimen provided relief?
No relief
OACOnset of symptoms unrelated to start of opioid 




What are the symptoms of OIC?
When did the OIC start?
Has the patient had a change from baseline in bowel habits since initiating 
opioid therapy characterized by any of the following:
•  Reduce BM frequency or worsening of straining to pass BMs
•  Sense of incomplete rectal evacuation
•  Harder stool consistency
Treated with lifestyle changes, diet modifications 
(fiber, water), stimulant and/or osmotic laxatives
Onset of symptoms with 




Perform specialist follow-up/testing as needed
•  Transit studies
•  Defecography 
•  Balloon expulsion test
Primary constipation?
•  Chronic idiopathic constipation
•  IBS
•  Pelvic floor dyssynergia 
Secondary constipation?
•  Refer to Table 1 for causes 
Fig. 3 Stepwise management of constipation in the elderly.
BM bowel movement, IBS irritable bowel syndrome, OAC opioid-
aggravated constipation, OIC opioid-induced constipation,
PAMORA peripherally acting l-opioid receptor antagonist. aRed
flags: history of unintentional weight loss, onset of constipation in
older patient, family history of cancer or inflammatory bowel
disease, bright red blood per rectum; physical examination: abnor-
mal abdominal examination/digital rectal examination, positive fecal
occult blood test, flexible sigmoidoscopy or colonoscopy
([50 years); initial laboratory values: decreased hemoglobin,
increased white blood cells, increased erythrocyte sedimentation
rate, increased thyroid-stimulating hormone, or abnormal potassium
or calcium. bIndicated for adults with OIC and advanced disease in
the palliative care setting when laxative response is insufficient;
adults with chronic noncancer pain. cIndicated for adults with OIC
and chronic noncancer pain (USA); adults with OIC when laxative
response is inadequate (European Union). dIndicated for adults with
OIC and chronic noncancer pain
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strategies in elderly patients is the information provided by
caregivers, who may often know more about the patient’s
symptoms and functional status than the patient does.
The healthcare provider should use this history to rule
out other causes of constipation, including medications,
such as anticholinergics and tricyclic antidepressants, and
comorbidities, such as diabetes mellitus and Parkinson
disease (Tables 1, 3) [25, 113]. The medical history should
also include any remedies (over-the-counter and prescrip-
tion) the patient has tried that have not relieved symptoms
of constipation [87, 113].
Because patients use variable definitions to describe the
subjective experience of constipation, the healthcare pro-
vider should use validated assessment tools, such as the
Bristol Stool Scale [133] (Fig. 4) and the Bowel Function
Index [132, 134], to diagnose the presence and severity of
constipation and establish a baseline for the assessment of
treatment outcomes. Healthcare providers should also
encourage patients to keep a diary of bowel habits for up to
2 weeks, using the Bristol Stool Chart to assess stool form
and consistency (Fig. 4) [133] and a diary of food and fluid
intake for at least 1 week to establish a baseline for mon-
itoring treatment success [135].
6.2 Stepwise Approach to Patient Management
The management of constipation in elderly patients
should be considered using a stepwise approach (Fig. 3).
Healthcare providers should be aware that patients with
OIC may continue to report symptoms of constipation,
despite efforts to manage the condition by using natural
remedies (e.g., increased fluids, fiber supplements),
behavioral approaches, and conventional laxatives [67].
Therefore, it is important to monitor the response of
elderly patients to conventional laxative approaches,
particularly those patients who may be especially vul-
nerable to AEs associated with these agents (Table 4). In
elderly patients with an inadequate response to conven-
tional laxatives or who are not suitable candidates for
laxative or lifestyle interventions, because of their specific
medical status, treatment options may include targeted
therapies (e.g., peripherally acting l-opioid receptor
antagonists) or lubiprostone (Table 4) [136].
To increase the potential for having a BM, elderly
patients should also be trained in the mechanics of bowel
evacuation. Patients should be instructed to sit on the toilet
with the feet elevated, to lean forward, placing the elbows
on the knees, and to bulge the abdomen and flatten the
spine; this position straightens the anorectal angle and
takes advantage of gravity, breathing, and diaphragmatic
control to facilitate evacuation of the bowel
[58, 135, 137, 138].
6.3 Specialist/Follow-Up Testing
When available treatment options fail, further tests in
collaboration with specialists may be warranted, including
transit studies (e.g., the SITZMARKS test), defecography
(i.e., to rule out diffuse GI dysmotility as the cause of
constipation), and anorectal physiology testing (e.g., a
balloon expulsion test to eliminate outlet obstruction as the
cause of constipation) to more thoroughly evaluate and
Bristol Stool Form Scale
Type 1 Separate hard lumps, like nuts (hard to pass)
Type 2 Sausage-shaped but lumpy
Type 3 Like a sausage but with cracks on its surface
Type 4 Like a sausage or snake, smooth and soft
Type 5 Soft blobs with clear-cut edges (passed easily)
Type 6 Fluffy pieces with ragged edges, a mushy stool
Type 7 Watery, no solid pieces; entirely liquid 
Fig. 4 Bristol Stool Form Scale
[133]. Stool images from the
National Institute of Diabetes
and Digestive and Kidney
Diseases, National Institutes of
Health. (Stool scale adapted
from [133], reprinted by
permission of Informa
Healthcare)
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provide individualized treatment of the elderly patient with
constipation [113, 139, 140].
7 Conclusions
Healthcare providers should be aware that constipation in
the elderly may occur secondary to underlying disease
conditions and use of medications other than those used to
treat chronic pain [57]. Moreover, the use of prescription
opioid analgesics for treatment of chronic pain in the
elderly is commonly associated with the development of
OIC [14, 21]. Thus, healthcare providers should obtain an
exhaustive patient history to establish whether the consti-
pation is a preexisting condition aggravated by medications
or a new condition secondary to treatment with opioids.
The patient assessment should include the use of validated
assessment tools (e.g., Bristol Stool Scale, Bowel Function
Index) not only to confirm the diagnosis but also to provide
a basis for evaluating treatment outcomes.
Healthcare providers should take a stepwise approach
when considering the various treatment options for OIC in
the elderly. Although laxatives are a first-line treatment
option in short-term use as needed and considered generally
well tolerated, evidence is lacking to support their effec-
tiveness in OIC [60, 63, 112, 141]. Moreover, it is important
to note that conventional laxatives may be inappropriate for
the treatment of OIC owing to the risk of AEs and other
considerations (e.g., chewing/swallowing disorders).
Approaches to long-term pain management that depend
on chronic use of opioid medications in elderly patients may
decrease the likelihood that OIC will resolve. Therefore,
long-term treatment with OIC-specific medication may be
an appropriate option in elderly patients. The availability of
the new pharmacologic agents methylnaltrexone, naloxegol,
and lubiprostone may provide more effective treatment
options for elderly patients with OIC and noncancer pain.
Maintenance of opioid-induced analgesia is an important
consideration in patients with OIC. Therefore, healthcare
providers should be aware that methylnaltrexone [116–118]
and naloxegol [121, 122, 124], because of their peripheral
mechanism of action, do not interfere with opioid-induced,
centrally mediated analgesia when administered to patients
with noncancer pain and OIC [116–118, 121, 122, 124]. The
complex multifactorial nature of constipation and its
potentially negative impact in elderly patients with OIC and
chronic pain, coupled with the availability of newer phar-
macologic agents that target the underlying mechanisms of
constipation (i.e., PAMORAs), and the locally acting sec-
retagogue lubiprostone, provide an opportunity for health-
care providers to better manage their elderly patients with
OIC and chronic pain.
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